RECURSION PHARMACEUTICALS, INC. Cash and Restricted Cash
RECURSION PHARMACEUTICALS, INC. (RXRX) had Cash and Restricted Cash of $556.82 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $556.82M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $665.18M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $753.92M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $667.14M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $556.82M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $665.18M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $753.92M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $667.14M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $533.85M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $509.16M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $603.02M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $435.83M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $482.75M 10-Q · filed 2025-08-05 | |
| 2024-03-31 | $306.15M 10-Q · filed 2025-05-05 | |
| 2023-12-31 | $401.43M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $397.21M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $416.82M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $482.38M 10-Q · filed 2024-05-09 | $482.38M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $559.11M 10-K · filed 2026-02-25 | |
| 2022-09-30 | $464.89M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $464.11M 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $518.13M 10-Q · filed 2023-05-08 | |
| 2021-12-31 | $295.35M 10-K · filed 2025-02-28 | |
| 2021-09-30 | $404.95M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $642.97M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $219.13M 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $267.17M 10-K · filed 2024-02-29 | |
| 2020-09-30 | $253.15M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $46.31M 10-Q · filed 2021-08-13 | |
| 2020-03-31 | $62.67M 10-Q · filed 2021-05-12 | |
| 2019-12-31 | $75.17M 10-K · filed 2023-02-27 | |
| 2018-12-31 | $15.71M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |